Coverage of all recommended variants
Standard guidelines recommend testing for variants in nine genes for newly diagnosed NSCLC patients.
The biomarkers are EGFR, ALK, KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, and HER2. Additionally, PD-L1 testing is recommended to guide the use of immune checkpoint inhibitors.
Lung HDPCR™ RNA Fusions
MET (Exon 14 Skipping)
ALK
RET
ROS1
NTRK 1,2,3
Lung HDPCR™ DNA Mutations
EGFR (Exon 19, T790M, L858R, G719X, S768I, L861Q, Exon 20)
KRAS (G12C)
BRAF (V600E)
HER2 (Exon 20)
IHC - Available upon request
PDL1
Easy – Protean obtains tissue specimens and performs testing in our CAP CLIA laboratory
Simple Ordering – Secure electronic portal with bi-directional communication with the Protean laboratory
Fast – Complete lung results within 2-3 days (as compared to an average of 17 days for NGS¹)
Evidence-based – Follows NCCN guidelines
Effective – Uncovers actionable information in over 90% of cases
Affordable – Covered by most insurance
For newly diagnosed NSCLC patients, the National Cancer Comprehensive Network (NCCN) guidelines recommend testing for alterations in nine genes to determine eligibility for targeted therapies. Molecular testing can detect these clinically relevant biomarkers identified by the NCCN in NSCLC patients, enabling insurance providers to determine eligibility for targeted therapies². Patients with actionable alterations that are treated with targeted therapy have 50% higher survival rates than those who receive chemotherapy or immunotherapy³.
Timely access to biomarker testing can help identify patients who could benefit from targeted therapies, informing treatment decisions that could lead to better patient outcomes and lower healthcare costs.
Interested in Lung HDPCR™?
Fill out your information below and someone will reach out to you to set up an appointment.
